Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

BACKGROUND: The inhibitor telaprevir (VX-950) of the hepatitis C virus (HCV) protease NS3-4A has been tested in a recent phase 1b clinical trial in patients infected with HCV genotype 1. This trial revealed residue mutations that confer varying degrees of drug resistance. In particular, two protease...

Descripción completa

Detalles Bibliográficos
Autores principales: Welsch, Christoph, Domingues, Francisco S, Susser, Simone, Antes, Iris, Hartmann, Christoph, Mayr, Gabriele, Schlicker, Andreas, Sarrazin, Christoph, Albrecht, Mario, Zeuzem, Stefan, Lengauer, Thomas
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395260/
https://www.ncbi.nlm.nih.gov/pubmed/18215275
http://dx.doi.org/10.1186/gb-2008-9-1-r16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395260/
https://www.ncbi.nlm.nih.gov/pubmed/18215275
http://dx.doi.org/10.1186/gb-2008-9-1-r16

Ejemplares similares